The portfolio consists of liquids and immediate release solid orals which are in the therapeutic segment to treat infections associated with UTIs
Celecoxib Capsules approval complements Strides’ existing products to serve a broader patient base
This approval authorizes the company to export Ibuprofen to the Chinese markets
Durable pain relief from a single MM-II injection and its cartilage-protective effects in OA modelsfeatured in two peer-reviewed articles
Carbamazepine Tablets USP, 200 mg have an estimated market size of US$ 32 million for twelve months ending December 2024 according to IQVIA
Pregabalin Gel 8% is a novel topical solution for diabetic neuropathic pain
The portfolio includes branded injectable cephalosporines for infectious diseases
The company expects to launch this product through its marketing partner in the near future
PRX-PLUS has a unique product feature with its deep-impacting formula
EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults
Subscribe To Our Newsletter & Stay Updated
